FLGT
Fulgent Genetics Exceeds Expectations in Q3 2026, Driven by Therapeutic Development Business and Strong Momentum in Clinical Pipeline
Fulgent Genetics, a leading genetics testing company, has reported its third quarter 2026 financial results, exceeding market expectations and showcasing strong momentum in its therapeutic development business. During the conference call to discuss the Q3 2026 earnings, Ming Hsieh, Chief Executive Officer of Fulgent Genetics, expressed satisfaction with the progress